针对PD-L1的聚合物--免疫纳米药物与放射治疗协同,用于持久的瘤控制
Jincheng Du1,2,3, Chuwen Luo2,3,4, Ya Liu2,3,4
1Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
Bioactive materials
|June 11, 2025
概括
这项研究引入了一种新的纳米药物,PEP-PLG-IMDQ,它将放射治疗与免疫治疗结合起来. 通过调节瘤免疫微环境,治疗显著抑制了瘤并改善了存活率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米医学是一种纳米医学.
- 辐射疗法 辐射疗法
背景情况:
- 放射治疗 (RT) 是一种至关重要的癌症治疗方法,但由于其对瘤免疫微环境的复杂影响,具有局限性.
- RT可以促进免疫性细胞死亡 (ICD),但也可提高PD-L1的调节,抑制抗瘤免疫力.
研究的目的:
- 开发一种新的纳米药物,PEP-PLG-IMDQ,可以将RT与免疫疗法协同使用.
- 克服RT诱导的免疫抑制并增强抗瘤反应.
主要方法:
- 开发PEP-PLG-IMDQ,一种使用聚L-胺酸的纳米平台,与PD-L1向和TLR7/8激动因子伊米达佐基诺林 (IMDQ) 相结合.
- 在CT26瘤携带小鼠中评估纳米药物的疗效,当与RT结合使用时.
- 评估免疫细胞透和记忆形成的机制研究.
主要成果:
- 在小鼠中,RT和PEP-PLG-IMDQ的组合实现了98.1%的瘤抑制和83%的长期存活率.
- 增强了CD8+T细胞的透 (比单独RT增加5.3倍).
- 建立了持久的免疫记忆,导致对瘤复发的抵抗力.
结论:
- PEP-PLG-IMDQ是一种可翻译的纳米医学策略,有效地将RT与免疫疗法进行协同作用.
- 这种方法通过时空免疫调节克服了辐射抵抗,增强了抗瘤免疫力.
- 这种组合治疗有望改善癌症治疗结果.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491